Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)

Lefaucheur, Jean-Pascal; Aleman, André; Baeken, Chris; Benninger, David H.; Brunelin, Jérôme; Di Lazzaro, Vincenzo; Filipović, Saša R.; Grefkes, Christian; Hasan, Alkomiet; Hummel, Friedhelm C.; Jääskeläinen, Satu K.; Langguth, Berthold; Leocani, Letizia; Londero, Alain; Nardone, Raffaele; Nguyen, Jean-Paul; Nyffeler, Thomas; Oliveira-Maia, Albino J.; Oliviero, Antonio; Padberg, Frank; ... (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clinical neurophysiology, 131(2), pp. 474-528. Elsevier 10.1016/j.clinph.2019.11.002

[img]
Preview
Text
1-s2.0-S1388245719312799-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150–206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a H1-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson’s disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DCR Unit Sahli Building > Forschungsgruppe Neurologie

UniBE Contributor:

Nyffeler, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1388-2457

Publisher:

Elsevier

Language:

English

Submitter:

Angela Amira Botros

Date Deposited:

04 Feb 2020 11:00

Last Modified:

04 Feb 2020 11:08

Publisher DOI:

10.1016/j.clinph.2019.11.002

PubMed ID:

31901449

BORIS DOI:

10.7892/boris.138033

URI:

https://boris.unibe.ch/id/eprint/138033

Actions (login required)

Edit item Edit item
Provide Feedback